Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Han-Jie Zhou"'
Autor:
Mark Rolfe, Daniel J. Anderson, Constantine S. Mitsiades, Jeffrey L. Wolf, Thomas G. Martin, Han-Jie Zhou, Laura Shawver, David Wustrow, F. Michael Yakes, Szerenke Kiss Von Soly, Christoph Driessen, Marianne Kraus, P. Leif Bergsagel, Marta Chesi, Jinhai Wang, Julie Rice, Christine Lam, Arun P. Wiita, Bing Yao, Grace J. Lee, Stephen T. Wong, Zhi Yong Wu, Mary-Kamala Menon, Ferdie Soriano, Emily M. King, Megan Murnane, Eduardo Valle, Eugen Dhimolea, Stevan Djakovic, Blake T. Aftab, Ronan Le Moigne
Supplementary Figure S1:Effect of CB-5083 on cell growth and survival in multiple myeloma and solid tumor cell lines; Supplementary Figure S2:CB-5083 activates UPR;Supplementary Figure S3:CB-5083 transcriptional response is unique in comparison to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::569299e78d46c92329042958fa03bafc
https://doi.org/10.1158/1535-7163.22509273
https://doi.org/10.1158/1535-7163.22509273
Autor:
Mark Rolfe, Daniel J. Anderson, Constantine S. Mitsiades, Jeffrey L. Wolf, Thomas G. Martin, Han-Jie Zhou, Laura Shawver, David Wustrow, F. Michael Yakes, Szerenke Kiss Von Soly, Christoph Driessen, Marianne Kraus, P. Leif Bergsagel, Marta Chesi, Jinhai Wang, Julie Rice, Christine Lam, Arun P. Wiita, Bing Yao, Grace J. Lee, Stephen T. Wong, Zhi Yong Wu, Mary-Kamala Menon, Ferdie Soriano, Emily M. King, Megan Murnane, Eduardo Valle, Eugen Dhimolea, Stevan Djakovic, Blake T. Aftab, Ronan Le Moigne
Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system, and CB-5083, a first-in-class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematologic and sol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9c3a3608da1883962d4e516df699248
https://doi.org/10.1158/1535-7163.c.6539250.v1
https://doi.org/10.1158/1535-7163.c.6539250.v1
Publikováno v:
Cancer Research. 82:429-429
Introduction: Androgen receptor (AR) signaling is a main driver of prostate cancer progression and remains a crucial target for therapeutic intervention even in late stages of the disease. Current antiandrogen therapies directly or indirectly target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3d71c121372003a69cbc095509a4830
https://doi.org/10.1158/1538-7445.am2022-429
https://doi.org/10.1158/1538-7445.am2022-429
Autor:
Amy Saur Conway, Lina Benajiba, Camille Vaganay, Daniel J. DeAngelo, Olivier Hermine, Yangzhong Tang, Kasper Lage, Han-Jie Zhou, Ilene Galinsky, Patrick Auberger, Jesse D. Vargas, Richard Stone, Josée Guirouilh-Barbat, Gabriela Alexe, Chaïma Benaksas, Yana Pikman, Alexandre Puissant, Bryann Pardieu, Daniel Anderson, Kimberly Stegmaier, Blandine Roux, Jana M. Ellegast, Bernard S. Lopez, Monica Schenone, Christina R. Hartigan, Michael T. Hemann, Linda Ross, Nina Fenouille, Mehdi Khaled, Frank Ling, Edyta Malolepsza, Frederic Luciano, Steven A. Carr, Gaetano Sodaro, Ronan Le Moigne, Tony Wu
Publikováno v:
Science Translational Medicine
Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (587), ⟨10.1126/scitranslmed.abg1168⟩
Sci Transl Med
Science Translational Medicine, American Association for the Advancement of Science, 2021, 13 (587), ⟨10.1126/scitranslmed.abg1168⟩
Sci Transl Med
The development and survival of cancer cells require adaptive mechanisms to stress. Such adaptations can confer intrinsic vulnerabilities, enabling the selective targeting of cancer cells. Through a pooled in vivo short hairpin RNA (shRNA) screen, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10c3d1c692e60e789dde8f10a34b3af
https://hal.archives-ouvertes.fr/hal-03420708
https://hal.archives-ouvertes.fr/hal-03420708
Autor:
Kunzhong Jian, Marianne D. Sadar, Peter Virsik, Teresa Tam, Jun Wang, Ronan Le Moigne, Raymond J. Andersen, Alessandra Cesano, Han-Jie Zhou, Nasrin R. Mawji, C. Adriana Banuelos
Publikováno v:
Journal of Urology. 203
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e9828686f0a19a7aa5fcc678ba319d3
https://doi.org/10.1097/ju.0000000000000971.04
https://doi.org/10.1097/ju.0000000000000971.04
Autor:
Nan Hyung Hong, Shihua Sun, Peter Virsik, Alessandra Cesano, Elahe A. Mostaghel, Stephen R. Plymate, Berenger Biannic, Han-Jie Zhou, Ronan Le Moigne
Publikováno v:
Molecular Cancer Therapeutics. 20:P192-P192
Background: Androgen receptor (AR) signaling is a main driver of prostate cancer progression and remains a crucial target for therapeutic intervention even in late stages of the disease. While current anti-androgen therapies targeting directly or ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dc4fe84984089cab7b285fb6e1f5a9f
https://doi.org/10.1158/1535-7163.targ-21-p192
https://doi.org/10.1158/1535-7163.targ-21-p192
Autor:
Ronan Le Moigne, Alessandra Cesano, Nan Hyung Hong, Han-Jie Zhou, Stephen R. Plymate, Peter Virsik, Elahe A. Mostaghel, Shihua Sun
Publikováno v:
Cancer Research. 81:1209-1209
The androgen receptor (AR) is a key driver in the growth of prostate cancer and remains a crucial target for therapeutic intervention even in late stages of the disease. While current anti-androgen therapies targeting directly or indirectly the AR li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efe268824bafb400da3ee2b8fb0eb623
https://doi.org/10.1158/1538-7445.am2021-1209
https://doi.org/10.1158/1538-7445.am2021-1209
Autor:
Peter Virsik, Marianne D. Sadar, Kunzhong Jian, C. Adriana Banuelos, Ronan Le Moigne, Nasrin R. Mawji, Raymond J. Andersen, Jun Wang, Han-Jie Zhou
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:The androgen receptor (AR) pathway continues to drive castration-resistant prostate cancer (CRPC) even in late stages of the disease. While the latest generation anti-an...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9715dd270c6a1033807a5c938618b97a
https://doi.org/10.1097/01.ju.0000555947.83770.aa
https://doi.org/10.1097/01.ju.0000555947.83770.aa
Autor:
Jesse D. Vargas, Kenny Lou, Kristy C. Perez, Han-Jie Zhou, Yangzhong Tang, Mary-Kamala Menon, Mark Rolfe, Ronan Le Moigne, Xianyun Jiao, Peter K Buchowiecki, Ariel Pios, Antonett Madriaga, Daniel Anderson, Grace J. Lee, Bing Yao, Laura K. Shawver, Zhi Yong Wu, Victoria A. Assimon
Publikováno v:
ACS chemical biology. 14(2)
RUVBL1 and RUVBL2 are ATPases associated with diverse cellular activities (AAAs) that form a complex involved in a variety of cellular processes, including chromatin remodeling and regulation of gene expression. RUVBLs have a strong link to oncogenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630229dc561b1b30df577fe68669c002
https://pubmed.ncbi.nlm.nih.gov/30640450
https://pubmed.ncbi.nlm.nih.gov/30640450
Autor:
Peter Virsik, Veronique Lauriault, Han-Jie Zhou, Ronan Le Moigne, Nan Hyung Hong, Alessandra Cesano, P. Pearson
Publikováno v:
Journal of Clinical Oncology. 39:119-119
119 Background: EPI-7386 is the newest of the “anitens”, a new class of compounds designed to inhibit androgen receptor activity by binding to the N-terminal domain (NTD) of the AR. Through this novel method of AR inhibition, anitens can block AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b510b288dbc7ca5d8953166c44cd67d3
https://doi.org/10.1200/jco.2021.39.6_suppl.119
https://doi.org/10.1200/jco.2021.39.6_suppl.119